Tag Archives: drugs

Pressemitteilungen

Multi-Billion Euro Corruption Scandal in the EU

Germany and the European Commission collusion to supress a medical device that will save billions on asthma drugs

Multi-Billion Euro Corruption Scandal in the EU

The new non-fiction book „European Politics on Drugs“ from Christoph Klein (Source: Copyright Photographer: Stephan Haeger, Deltawerk)

„There seems to be no limits to their greed and they are doing this to a technology that has proven health benefits, continuing to keep it out of the hands of everyone suffering from asthma and COPD worldwide … If I had explained these events without mentioning Germany and the EU, most people would think I was describing some banana republic or total-itarian regime in the third world.“ – Christoph Klein

About the author: In the early 1990s, Christoph Klein developed an improved inhaler actuator for asthma sprays that realized tremendous savings on pharmaceutical drugs. After the initial excitement surrounding his invention subsided, the device was soon denounced as dangerous (but never any proof) by the pharma industry and the German authorities followed suit. Banned in 1997 with the active support of the European Commission, Germany, and Upper Bavaria in particular, these authorities have succeeded in keeping this effective medical device off of the global market for over two decades.

In 2012, the European Parliament estimated that the ban on Klein“s inhaler had already cost European health insurance programs and their contributors approximately 50 billion euros.

Christoph Klein was born near Cologne, Germany, in 1966. Inventor, entrepreneur, consultant and asthma sufferer himself, Klein has invented several innovative devices to help in the treatment of asthma and COPD. Fighting for justice in courtrooms across Europe for over 20 years, he lives with his wife and two children near Salzburg, Austria.

The Book: European Politics on Drugs is a memoir based on the ongoing scandal known as the „atmed Affair,“ coined by the former Portuguese European Commission President Jose Manuel Barroso in 2007. It is the story of how a seemingly innocent sales ban over public health concerns in Bavaria has prevented a simple invention from gaining access to world-wide markets. A real-life economic thriller that is far from over, the scandal continues to reveal the ugly truths hidden in the EU system. In recounting his 25-year Odyssey, Klein documents a dysfunctional EU, exposing the blatant corruption at its core.

With Brexit and a trade war looming with the United States, Europe is currently facing an existential crisis. People are starting to realize that the power centred in Brussels has become an uncontrollable monstrosity and is largely dominated by German economic interests. In the background, a growing EU political elite, determined to wield its influence over Europe“s destiny, is increasingly acting without regard for the national sovereignty of EU member states and their elected leaders. While serving large economic interests by defending industrial monopolies, the EU is also pursuing a policy of protectionism that is ultimately undermining the rule of law. This is manifested in the manipulation of global trade, where investment security and legal certainty have become anything but certain. Slowly but surely, the European Union is betraying its own raison d“etre.

The new non-fiction book „European Politics on Drugs“ ist now avaible at Amazon

Christoph Klein ist freier Autor, Erfinder, Unternehmer und Berater aus Grossgmain, Österreich

Contact
Christoph Klein
Christoph Klein
Poststraße 62
5084 Großgmain
Phone: +49 163 5453849
E-Mail: contact@christoph-klein.info
Url: https://www.christoph-klein.info

Pressemitteilungen

Global Respiratory Drugs Market 2018 – Novartis AG, GlaxoSmithKline plc, Astra Zenca PLC

Global Respiratory Drugs Market research report gives a systematic and competent approach to gather important statistics of Global Respiratory Drugs industry. The research report analyses the historical as well as present performance of the Global Respiratory Drugs industry, and also interprets different market scenarios along with future market trends.

First of all „Global Respiratory Drugs Market 2018″ focused on global and regional market, major dominant manufacturers, Respiratory Drugs market classification and applications. The research report analyzes the basic scope of this industry like product definition, specification, product scope and Respiratory Drugs industry chain structure.

Request for the sample report: https://apexmarketreports.com/Life-Science/Global-Respiratory-Drugs-Market-2018-2024#sample

Key manufacturers are included based on manufacturing sites, capacity and production, product specifications:
Novartis AG
F.Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Astra Zenca PLC
Vertex Pharmaceuticals Inc.

Global Respiratory Drugs research report performs SWOT analysis for the Respiratory Drugs international market to gain better insights on Strengths, Opportunities, development history, Respiratory Drugs industry competitive landscape analysis.

Further, The global Respiratory Drugs market 2018 is also analyzed on the basis of Respiratory Drugs Market dynamics, product pricing, Respiratory Drugs production capacity, supply to demand ratio, and the revenue generated by the product. Major highlights of the Respiratory Drugs Market report include market perceptions such as import/export details, supply and consumption figures, market performance and cost of the product, market overview, price, revenue and Respiratory Drugs market’s gross margin by regions (North America, Europe, China, India and Asia Other), as well as other regions can be added in Respiratory Drugs Market area.

Do Inquiry Before Buying: https://apexmarketreports.com/Life-Science/Global-Respiratory-Drugs-Market-2018-2024#inquiry

Then, the report contains Company profiles of top manufacturers with information such as sales and annual revenue, sales and consumer volume and product picture as well as specification.

The competitive landscape of the global Respiratory Drugs market is determined by evaluating the various market Capacity, Production, Capacity Utilization Rate, Price, revenue and contact information, Cost and Gross Margin Analysis. This report also includes Respiratory Drugs industry’s Upstream Raw Materials Sourcing, Industrial Chain, Sourcing Strategy and Downstream Buyers.

Finally, „Global Respiratory Drugs market“ report includes feasibility of new investment projects, key strategies used by leading players and research conclusions are offered.

Wissenschaft/Forschung

United States Antiepileptic and Anticonvulsant Drugs Market Report to 2021

„The Report United States Antiepileptic and Anticonvulsant Drugs Market Report to 2021 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz“

This report studies sales (consumption) of Antiepileptic and Anticonvulsant Drugs in USA market, focuses on the top players, with sales, price, revenue and market share for each player, covering

Novartis

Pfizer, Inc.

Roche

Sanofi

Merck & Co., Inc.

GlaxoSmithKline plc

Johnson & Johnson

AstraZeneca plc.

Eli Lilly and Company

Abbvie

AMGen

Teva Pharmaceutical Industries Ltd.

Bayer AG

Bristol-Myers Squibb

Astellas Pharma

Daiichi Sankyo

Abbott Laboratories

Yangtze River Pharmaceutical Group

Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/869016

Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into

Barbiturates and Analogues Thereof

Others

Type III

Split by applications, this report focuses on sales, market share and growth rate of Antiepileptic and Anticonvulsant Drugs in each application, can be divided into

First Level Hospital

Two Level Hospital

Three Level Hospital

Table of Contents

United States Antiepileptic and Anticonvulsant Drugs Market Report 2021

1 Antiepileptic and Anticonvulsant Drugs Overview

1.1 Product Overview and Scope of Antiepileptic and Anticonvulsant Drugs

1.2 Classification of Antiepileptic and Anticonvulsant Drugs

1.2.1 Barbiturates and Analogues Thereof

1.2.2 Others

1.2.3 Type III

1.3 Applications of Antiepileptic and Anticonvulsant Drugs

1.3.1 First Level Hospital

1.3.2 Two Level Hospital

1.3.3 Three Level Hospital

1.3.4 Others

1.4 USA Market Size (Value and Volume) of Antiepileptic and Anticonvulsant Drugs (2011-2021)

1.4.1 USA Antiepileptic and Anticonvulsant Drugs Sales, Revenue and Price (2011-2021)

1.4.2 USA Antiepileptic and Anticonvulsant Drugs Sales and Growth Rate (2011-2021)

1.4.3 USA Antiepileptic and Anticonvulsant Drugs Revenue and Growth Rate (2011-2021)

2 USA Antiepileptic and Anticonvulsant Drugs Competition by Manufacturers

2.1 USA Antiepileptic and Anticonvulsant Drugs Sales and Market Share of Key Manufacturers (2015 and 2016)

2.2 USA Antiepileptic and Anticonvulsant Drugs Revenue and Share by Manufactures (2015 and 2016)

3 USA Antiepileptic and Anticonvulsant Drugs (Volume and Value) by Type

3.1 USA Antiepileptic and Anticonvulsant Drugs Sales and Market Share by Type (2011-2021)

3.2 USA Antiepileptic and Anticonvulsant Drugs Revenue and Market Share by Type (2011-2021)

4 USA Antiepileptic and Anticonvulsant Drugs (Volume) by Application

5 USA Antiepileptic and Anticonvulsant Drugs Manufacturers Analysis

5.1 Novartis

5.1.1 Company Basic Information, Manufacturing Base and Competitors

5.1.2 Antiepileptic and Anticonvulsant Drugs Product Type and Technology

5.1.2.1 Barbiturates and Analogues Thereof

5.1.2.2 Others

5.1.3 Antiepileptic and Anticonvulsant Drugs Sales, Revenue, Price of Novartis (2015 and 2016)

5.2 Pfizer, Inc.

5.2.1 Company Basic Information,Manufacturing Base and Competitors

5.2.2 Pharmaceuticals Product Type and Technology

5.2.2.1 Barbiturates and Analogues Thereof

5.2.2.2 Others

5.2.3 Pharmaceuticals Sales, Revenue, Price of Pfizer, Inc. (2015 and 2016)

5.3 Roche

5.3.1 Company Basic Information,Manufacturing Base and Competitors

5.3.2 Roche Product Type and Technology

5.3.2.1 Barbiturates and Analogues Thereof

5.3.2.2 Others

5.3.3 Roche Sales, Revenue, Price of Roche (2015 and 2016)

5.4 Sanofi

5.4.1 Company Basic Information,Manufacturing Base and Competitors

5.4.2 Eli Lilly and Company Product Type and Technology

5.4.2.1 Barbiturates and Analogues Thereof

5.4.2.2 Others

5.4.3 Sanofi Sales, Revenue, Price of Sanofi (2015 and 2016)

5.5 Merck & Co., Inc.

5.5.1 Company Basic Information,Manufacturing Base and Competitors

5.5.2 Merck & Co., Inc. Product Type and Technology

5.5.2.1 Barbiturates and Analogues Thereof

5.5.2.2 Others

5.5.3 Merck & Co., Inc. Sales, Revenue, Price of Merck & Co., Inc. (2015 and 2016)

5.6 GlaxoSmithKline plc

Read our latest Press Release at http://www.marketresearchreports.biz/pressreleases

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Wissenschaft/Forschung

United States Drugs for the Treatment of Asthma Market Status, Opportunities, Market Forecasts Report to 2021

„The Report United States Drugs for the Treatment of Asthma Market Report to 2021 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz“

This report studies sales (consumption) of Drugs for the Treatment of Asthma in USA market, focuses on the top players, with sales, price, revenue and market share for each player, covering

Novartis

Pfizer, Inc.

Roche

Sanofi

Merck & Co., Inc.

GlaxoSmithKline plc

Johnson & Johnson

AstraZeneca plc.

Eli Lilly and Company

Abbvie

AMGen

Teva Pharmaceutical Industries Ltd.

Bayer AG

Bristol-Myers Squibb

Astellas Pharma

Daiichi Sankyo

Abbott Laboratories

Yangtze River Pharmaceutical Group

BAX

Taish Seiyaku Kabushiki-gaisha

Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/869037

Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into

Beta2 Adrenergic Receptor Agonist

M Cholinergic Receptor Antagonist

Drugs that Affect Leukotrienes

Glucocorticoid Drugs

Phosphodiesterase Inhibitors

Split by applications, this report focuses on sales, market share and growth rate of Drugs for the Treatment of Asthma in each application, can be divided into

First Level Hospital

Two Level Hospital

Three Level Hospital

Others

Table of Contents

United States Drugs for the Treatment of Asthma Market Report 2021

1 Drugs for the Treatment of Asthma Overview

1.1 Product Overview and Scope of Drugs for the Treatment of Asthma

1.2 Classification of Drugs for the Treatment of Asthma

1.2.1 Beta2 Adrenergic Receptor Agonist

1.2.2 M Cholinergic Receptor Antagonist

1.2.3 Drugs that Affect Leukotrienes

1.2.4 Glucocorticoid Drugs

1.2.5 Phosphodiesterase Inhibitors

1.3 Applications of Drugs for the Treatment of Asthma

1.3.1 First Level Hospital

1.3.2 Two Level Hospital

1.3.3 Three Level Hospital

1.3.4 Others

1.4 USA Market Size (Value and Volume) of Drugs for the Treatment of Asthma (2011-2021)

1.4.1 USA Drugs for the Treatment of Asthma Sales, Revenue and Price (2011-2021)

1.4.2 USA Drugs for the Treatment of Asthma Sales and Growth Rate (2011-2021)

1.4.3 USA Drugs for the Treatment of Asthma Revenue and Growth Rate (2011-2021)

2 USA Drugs for the Treatment of Asthma Competition by Manufacturers

2.1 USA Drugs for the Treatment of Asthma Sales and Market Share of Key Manufacturers (2015 and 2016)

2.2 USA Drugs for the Treatment of Asthma Revenue and Share by Manufactures (2015 and 2016)

3 USA Drugs for the Treatment of Asthma (Volume and Value) by Type

3.1 USA Drugs for the Treatment of Asthma Sales and Market Share by Type (2011-2021)

3.2 USA Drugs for the Treatment of Asthma Revenue and Market Share by Type (2011-2021)

4 USA Drugs for the Treatment of Asthma (Volume) by Application

5 USA Drugs for the Treatment of Asthma Manufacturers Analysis

5.1 Novartis

5.1.1 Company Basic Information, Manufacturing Base and Competitors

5.1.2 Drugs for the Treatment of Asthma Product Type and Technology

5.1.2.1 Beta2 Adrenergic Receptor Agonist

5.1.2.2 M Cholinergic Receptor Antagonist

5.1.3 Drugs for the Treatment of Asthma Sales, Revenue, Price of Novartis (2015 and 2016)

5.2 Pfizer, Inc.

5.2.1 Company Basic Information,Manufacturing Base and Competitors

5.2.2 Pharmaceuticals Product Type and Technology

5.2.2.1 Beta2 Adrenergic Receptor Agonist

5.2.2.2 M Cholinergic Receptor Antagonist

5.2.3 Pharmaceuticals Sales, Revenue, Price of Pfizer, Inc. (2015 and 2016)

5.3 Roche

5.3.1 Company Basic Information,Manufacturing Base and Competitors

5.3.2 Roche Product Type and Technology

5.3.2.1 Beta2 Adrenergic Receptor Agonist

5.3.2.2 M Cholinergic Receptor Antagonist

5.3.3 Roche Sales, Revenue, Price of Roche (2015 and 2016)

Read our latest Press Release at http://www.marketresearchreports.biz/pressreleases

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Pressemitteilungen

Malaysia’s cutting edge products and outsourcing services at CPhI

Malaysia continues to push hard to strengthen its presence in the EU’s Euro 225 billion plus import market.

Malaysian booth at the CPhI 2013

TUESDAY, OCTOBER 22, FRANKFURT: A total of 10 Malaysian exhibitors will be taking part at the CPhi 2013 trade fair at Frankfurt. Malaysia’s pavilion will be in Hall 4.0 D24 and is organised by the Malaysian Ministry of Health and Malaysia External Trade Development Corporation (MATRADE).

According to S. Jai Shankar, the Trade Commissioner at MATRADE’s Frankfurt office, Malaysian pharmaceutical industry has moved up the value chain over the last decade. According to him currently the industry has the capacity to produce medicines in all dosage forms e.g. tablets (coated & non-coated), capsules (hard and soft gelatine), liquids, creams, ointments, sterile eye drops, small volume injectable (ampoules and vials), large volume infusions, dry powders for reconstitution and active pharmaceutical ingredients (API).

Local manufacturers have also developed and launched off-patent generics and herbal products using their own brands. Currently, the local industry is producing about 30 per cent of the domestic demand, as well as exporting to the Asia-Pacific Rim countries, the Middle East, Africa, Latin America and Europe. Leading Malaysian companies are also moving into the production of biologics drugs, oncology and high value-added generic compounds in-line with the growing demands in this region. 246 pharmaceutical premises with Good Manufacturing Practices certification have registered with the Malaysia“s Drug Control Authority (DCA).

According to Mr. Shankar, of these, a total of 51 premises are licensed to produce modern medicines comprising mainly analgesics, antacids, anti-hypertensive, diuretics, antibiotics and anti-histamines in the form of tablets, capsules, drops, powders, creams, ointments, injectable, syrups, ophthalmic and nasal preparations. The remaining 172 premises are licensed to produce local traditional and herbal medicines.

„Malaysia is one of the few countries in the region that have been accepted into the Pharmaceutical Inspection Cooperation/Scheme (PIC/S),“ he says. The country’s exports of pharmaceutical products received a boost, especially among the member countries, which include the EU, Australia and Canada with the admission of Malaysia as a member of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Cooperation/Scheme (PIC/S) in January 2002,

There is also growing demand for Malaysia’s expertise in production of halal pharmaceuticals and Malaysia’s halal certifications. Under the Healthcare National Key Economic Area (NKEA) sector, one of the key recommendations is to promote manufacturing of pharmaceuticals. New investments in the state-of-the-art technologies and compliance with international standards have enabled Malaysian companies to be strategic outsourcing partners for MNCs. Furthermore, Malaysia has established 27 Clinical Research Centres (CRC) to conduct clinical trials, clinical epidemiology and economic research, and manage complex medical databases.

According to Mr. Shankar, essentially these developments mean Malaysian pharmaceutical companies are more than capable of now only supplying products but also a wide-range of R&D and manufacturing services to the global pharmaceutical companies. At the CPhI, Malaysia is represented by some of its largest manufactures in the pharmaceutical industry. Details of the companies are as below:

CCM PHARMACEUTICALS SDN BHD
1. Ethical, OTC and Food Supplements (all major therapeutic class and health supplements for children and adult).
2. OSD (tablet, capsule, & softgel)
3. Liquid
4. Cream

DUOPHARMA (M) SDN BHD
1. Ethical range covering all major therapeutic class
2. OSD (Tablet & Capsule)
3. Injectable
4. Liquid

KOTRA PHARMA (M) SDN BHD
1. Axcel – prescription medicine
2. Vaxcel – prescription injectable
3. Appeton – healthcare supplements

MEDICAL DEVICES CORPORATION SDN BHD
1. Continuous Ambulatory Peritoneal Dialysis (CAPD)
2. Metabolic solution bag for Intraveneous (IV)
3. Flexible medical solutions bags Irrigation and Veterinary

NATURAL WELLNESS INDUSTRIES SDN BHD
1. Traditional herbs supplements
2. Health care products
3. Toiletries
4. Cosmetics

PHARMANIAGA MANUFACTURING BERHAD
Simvastatin (Health care product) & packaging services

IDAMAN PHARMA MANUFACTURING SDN BHD
Azithromycin (Medicine) & packaging services

XEPA-SOUL PATTINSON (M) SDN BHD
Sommeil (Medicine)

AIN MEDICARE SDN BHD
1. Intravenous solutions
2. Irrigation solutions
3. Small volume products

SFS GLOBAL LOGISTICS SDN BHD
www.sfsgl.com
Total logistic provider for sea, air and land.

About MATRADE

MATRADE was established on March 1, 1993 as the external trade promotion arm of Malaysia’s Ministry of International Trade and Industry (MITI). Its functions are:
-To promote, assist and develop Malaysia’s external trade with particular emphasis on the export of manufactured and semi-manufactured products and services;
-To formulate and implement export marketing strategies and trade promotion activities to promote Malaysia’s export;
-To undertake commercial intelligence and market research and create a comprehensive database of information for the improvement and development of Malaysia’s trade;
-To organise training programmes to improve the international marketing skills of Malaysian exporters;
-To enhance and protect Malaysia’s international trade investment abroad; and
-To promote, facilitate and assist in the services areas related to trade.

NOTE TO EDITORS (not to be published)

For more information, please contact:
Ms.Janine Knorreck
Marketing Officer, MATRADE Frankfurt
Tel (Direct):015770226070
Email:frankfurt.janine@matrade.gov.my
Web: www.matrade.gov.my

Media Agency for content and design

Kontakt:
Globetrade
Uwe Fischer
Kruppstr. 72
40227 Düsseldorf
01577-0226207
info@globetra.de
http://www.globetra.de